Summary
ILU Chart
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024.
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity.
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Illumina, Inc. Dividends
Illumina, Inc. Earnings
| 5 Aug 2025 (In 1 month) Date | | 1.01 Cons. EPS | - EPS |
| 4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | - Cons. EPS | - EPS |
| 5 Aug 2025 (In 1 month) Date | | 1.01 Cons. EPS | - EPS |
| 4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | - Cons. EPS | - EPS |
Illumina, Inc. (ILU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Illumina, Inc. ever had a stock split?
Illumina, Inc. Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Mr. Jacob Thaysen Ph.D. CEO | XSTU Exchange | US4523271090 ISIN |
| US Country | 8,970 Employees | - Last Dividend | 25 Jun 2024 Last Split | 28 Jul 2000 IPO Date |
Overview
Illumina, Inc. is a leader in the development and manufacturing of sequencing- and array-based solutions designed for genetic and genomic analysis. With operations spanning the United States, Singapore, the United Kingdom, and other international markets, Illumina serves a diverse set of customers, including genomic research centers, academic institutions, government laboratories, hospitals, as well as players in the pharmaceutical and biotechnology industries, commercial molecular diagnostic laboratories, and consumer genomics companies. The company's product offerings are critical in facilitating comprehensive genomic studies, contributing significantly to advancements in genetic health and personalized medicine. Founded in 1998, Illumina has its headquarters in San Diego, California, and operates through two main segments: Core Illumina and GRAIL, the latter focusing on the development of Galleri, a groundbreaking multi-cancer early detection test. Illumina's commitment to innovation is evident in its continuous efforts to develop new solutions aimed at accelerating cancer diagnoses and enhancing blood-based detection methods for minimal residual disease, among other post-diagnostic applications.
Products and Services
Illumina's portfolio encompasses a comprehensive range of sequencing and array-based instruments, consumables, and services tailored for genomic analysis. These include:
- Sequencing and Array-based Instruments and Consumables: This category covers reagents, flow cells, and library preparation kits necessary for carrying out genomic sequencing and analysis. These tools enable researchers and clinicians to explore an organism's genetic material in comprehensive or targeted ways, depending on the needs of their studies or diagnostics.
- Whole-Genome Sequencing Kits: These kits are designed for sequencing the entire genomes of organisms ranging in size and complexity. Whole-genome sequencing is critical for understanding genetic predispositions to diseases, identifying mutations, and conducting other comprehensive genomic studies.
- Targeted Resequencing Kits: For studies focusing on exomes, specific genes, RNA, or other particular genomic regions, Illumina offers targeted resequencing kits. These kits are vital for focused genetic analysis, enabling precise study of regions of interest within the genome.
- Genomic Services: Beyond products, Illumina offers a range of services, including whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. These services facilitate the application of Illumina's technologies across various research and medical scenarios, ensuring users can leverage the full potential of genomic analysis.
- Galleri: A pioneering multi-cancer early detection test developed by GRAIL, a segment of Illumina, that aims to revolutionize cancer diagnostics. Galleri is designed to detect signals of cancer in the body before symptoms appear, offering the potential for significantly improved outcomes through earlier detection.
All products and services offered by Illumina are marketed and distributed directly to customers, as well as through life-science distributors, ensuring a wide-reaching impact on the field of genomics.
Contact Information
